October 2025 in “Dermatologica Sinica” A personalized treatment combining traditional and new therapies may improve hair loss outcomes in alopecia areata.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
June 2025 in “Patient Preference and Adherence” Chinese patients with alopecia areata value JAK inhibitors but worry about side effects and relapse, highlighting the need for education and support.
April 2025 in “BMC Immunology” Targeting SIRT1 with antisense oligonucleotides could be a promising treatment for hair loss.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
September 2025 in “Wound Repair and Regeneration” GLP-1 receptor agonists may help manage and prevent diabetic foot ulcers.
28 citations
,
January 2009 in “Cellular & Molecular Biology Letters” DHT deficiency increases iNOS expression in rat testis and epididymis.
3 citations
,
April 2023 in “Cytotechnology”
January 2025 in “Clinical Cosmetic and Investigational Dermatology” Pediatric alopecia areata is more immune-active than adult cases, suggesting age-specific treatments and potential use of JAK inhibitors.
38 citations
,
January 2019 in “International Journal of Women's Dermatology” The document concluded that more research is needed to find the best treatment for Frontal fibrosing alopecia.
17 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
16 citations
,
August 2023 in “JAAD Case Reports” JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.
March 2025 in “JEADV Clinical Practice” People with primary scarring alopecia have higher risks of other health issues like vitamin D deficiency and thyroid disease.
8 citations
,
November 2018 in “BMC Pulmonary Medicine” A 70-year-old woman with bronchiectasis developed a rare immune disease due to a bacterial infection, requiring a difficult balance of treatments.
355 citations
,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
May 2025 in “Preprints.org” Unique microRNA patterns can help diagnose and treat severe alopecia areata.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
19 citations
,
December 2015 in “Journal of Investigative Dermatology” The protein p53 directly reduces the production of Keratin 17, a skin and hair protein, in rats with radiation dermatitis.
9 citations
,
May 2023 in “Stem Cell Research & Therapy” Stem cell treatment from umbilical cords reduces symptoms of atopic dermatitis and may help hair growth.
7 citations
,
August 2023 in “Journal of the American Academy of Dermatology” JAK inhibitors offer new hope for treating severe alopecia areata.
1 citations
,
November 2025 in “Stem Cell Research & Therapy” Immortalized hair follicle cells could be useful for regenerative medicine and treating inflammation and oxidative stress.
1 citations
,
May 2025 in “Journal of Cosmetic Dermatology” Blood metabolites significantly influence alopecia areata risk.
1 citations
,
April 2024 in “Journal of Autoimmunity” Interleukin-15 can help hair growth and protect hair follicles.
October 2025 in “Journal of Clinical Medicine” Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.
July 2025 in “Malaria Journal” Resolving malaria-related lung issues doesn't rely on Alox12 and leaves some inflammation.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
April 2025 in “Journal of Dermatology for Physician Assistants” Vitiligo and alopecia should be covered by Medicaid and TRICARE as medical, not cosmetic, conditions.
January 2026 in “Aging and Disease” Targeting mitochondria can improve skin health and slow aging.
August 2024 in “Cell Death and Disease” Activating TLR9 helps heal wounds and regrow hair by using specific immune cells.